EGFR and cancer: In an attempt to develop potent and selective antitumor agents, a series of quinazoline- and thiourea-containing sorafenib derivatives (as shown in Figure 2) were designed and synthesized, and their inhibitory activities against EGFR, VEGFR-2, and three cancer cell lines were evaluated.